Genesis Pharmaceuticals Enterprises, Inc.

Form 3

January 28, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Xin Jingsheng

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

01/28/2008

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Genesis Pharmaceuticals Enterprises, Inc. [GTEC.OB]

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

MIDDLE SECTION, LONGMAO ST, AREA A. LAIYANG WAIXIANGXING **INDUSTRIAL PARK**

(Street)

(Check all applicable)

Director _X__ Officer

10% Owner Other (give title below) (specify below) Director of Equipment

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

4. Nature of Indirect Beneficial

LAIYANG CITY, SHANDONG PROV, Â F4Â 710075

(City) (State)

1. Title of Security

(Instr. 4)

(Zip)

2. Amount of Securities

Beneficially Owned (Instr. 4)

3. Ownership

Form:

Table I - Non-Derivative Securities Beneficially Owned

Ownership (Instr. 5)

Direct (D) or Indirect (I)

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 4)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security**

Conversion or Exercise Price of

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form 3

| Date | Expiration | Title | Amount or | Derivative | Security: |
|-------------|------------|-------|-----------|------------|-------------|
| Exercisable | Date | | Number of | Security | Direct (D) |
| | | | Shares | | or Indirect |
| | | | | | (I) |
| | | | | | (Instr. 5) |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|--------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Xin Jingsheng MIDDLE SECTION, LONGMAO ST, AREA A LAIYANG WAIXIANGXING INDUSTRIAL PARK LAIYANG CITY, SHANDONG PROV, F4 710075 | Â | Â | Director of Equipment | Â |

Signatures

/s/ Xin
Jengsheng

**Signature of Reporting Person

O1/28/2008

Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2